Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function

Nature Chemical Biology

Volumn 8, Issue 11, 2012, Pages 920-925

  Saalau Bethell, Susanne M ^a   Woodhead, Andrew J ^a   Chessari, Gianni ^a   Carr, Maria G ^a   Coyle, Joseph ^a   Graham, Brent ^a   Hiscock, Steven D ^a   Murray, Christopher W ^a   Pathuri, Puja ^a   Rich, Sharna J ^a   Richardson, Caroline J ^a   Williams, Pamela A ^a   Jhoti, Harren ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; HELICASE; LIGAND; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; PROTEINASE INHIBITOR; TELAPREVIR; VIRUS PROTEIN;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; HEPATITIS C; HEPATITIS C VIRUS; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REPLICON; STRUCTURE ANALYSIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY;

HEPATITIS C VIRUS;

EID: 84867683811     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1081     Document Type: Article

References (44)

1. Reed, K.E. & Rice, C.M. Overview of hepatitis C virus genome structure, polyprotein processing and protein properties. Curr. Top. Microbiol. Immunol. 242, 55-84 (2000). (Pubitemid 29467521)
2. Bartenschlager, R. & Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 81, 1631-1648 (2000). (Pubitemid 30427068)
3. Morgenstern, K.A. et al. Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of the hepatitis C virus NS3-4A complex isolated from transfected COS cells. J. Virol. 71, 3767-3775 (1997). (Pubitemid 27172390)
4. Beran, R.K. & Pyle, A.M. Hepatitis C viral NS3-4a protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 283, 29929-29937 (2008).
5. Beran, R.K., Serebrov, V. & Pyle, A.M. Te serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J. Biol. Chem. 282, 34913-34920 (2007). (Pubitemid 350232430)
6. Rajagopal, V., Gurjar, M., Levin, M.K. & Patel, S.S. Te protease domain increases the translocation stepping efciency of the hepatitis C virus NS3-4A helicase. J. Biol. Chem. 285, 17821-17832 (2010).
7. Hopkins, A.L. et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39, 1589-1600 (1996).
8. Kessl, J.J. et al. An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol. Pharmacol. 76, 824-832 (2009).
9. Walker, M.A. New approaches for inhibiting HIV integrase: a journey beyond the active site. Curr. Opin. Investig. Drugs 10, 129-136 (2009).
10. Chen, K.X. & Njoroge, F.G. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs 10, 821-837 (2009).
11. Lamarre, D. et al. An NS3 protease inhibitor with antiviral efects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003). (Pubitemid 37442587)
12. Tibeault, D. et al. Use of the fused NS4a peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-4a. Biochemistry 48, 744-753 (2009).
13. Belon, C.A. & Frick, D.N. Helicase inhibitors as specifcally targeted antiviral therapy for hepatitis C. Future Virol. 4, 277-293 (2009).
14. Frick, D.N. Te hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 9, 1-20 (2007). (Pubitemid 46139067)
15. Raney, K.D., Sharma, S.D., Moustafa, I.M., Cameron, C.E. & Hepatitis, C. Virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J. Biol. Chem. 285, 22725-22731 (2010).
16. Chappell, K.J. et al. West Nile virus NS2B/NS3 protease as an antiviral target. Curr. Med. Chem. 15, 2771-2784 (2008).
17. Chernov, A.V. et al. Te two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J. Biol. Chem. 283, 17270-17278 (2008).
18. Murray, C.W. & Blundell, T. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 20, 497-507 (2010).
19. Murray, C.W. & Rees, D.C. Te rise of fragment-based drug discovery. Nat. Chem. 1, 187-192 (2009).
20. Rhodes, D.I. et al. Structural basis for a new mechanism of inhibition of HIV-1 integrase identifed by fragment screening and structure-based design. Antivir. Chem. Chemother. 21, 155-168 (2011).
21. Perryman, A.L. et al. Fragment-based screen against HIV protease. Chem. Biol. Drug Des. 75, 257-268 (2010).
22. Krimm, I., Lancelin, J.-M. & Praly, J.-P. Bindingevaluation of fragment-based scafolds for probing allosteric enzymes. J. Med. Chem. 55, 1287-1295 (2012).
23. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109, 5299-5304 (2012).
24. Pommier, Y. & Marchand, C. Interfacial inhibitors: targeting macromolecular complexes. Nat. Rev. Drug Discov. 11, 25-36 (2012).
25. Yao, N., Reichert, P., Taremi, S.S., Prosise, W. W. & Weber, P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999). (Pubitemid 29529876)
26. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNA in a hepatoma cell line. Science 285, 110-113 (1999). (Pubitemid 29307577)
27. Bartenschlager, R. Hepatitis C replicons: potential role for drug development. Nat. Rev. Drug Discov. 1, 911-916 (2002). (Pubitemid 37361585)
28. De Clercq, E. Te design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6, 1001-1018 (2007).
29. Richman, D.D. Te impact of drug resistance on the efectiveness of chemotherapy for chronic hepatitis B. Hepatology 32, 866-867 (2000).
30. Kuiken, C., Yusim, K., Boykin, L. & Richardson, R. Te Los Alamos HCV sequence database. Bioinformatics 21, 379-384 (2005). (Pubitemid 40246609)
31. Ding, S.C., Kohlway, A.S. & Pyle, A.M. Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus. J. Virol. 85, 4343-4353 (2011).
32. Luo, D. et al. Flexibility between the protease and helicase domains of the Dengue virus NS3 protein conferred by the linker region and its functional implications. J. Biol. Chem. 285, 18817-18827 (2010).
33. Wang, W. et al. Conserved C-terminal threonine of hepatitis C virus NS3 regulates autoproteolysis and prevents product inhibition. J. Virol. 78, 700-709 (2004). (Pubitemid 38067591)
34. Wölk, B. et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74, 2293-2304 (2000). (Pubitemid 30091484)
35. Brass, V. et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl. Acad. Sci. USA 105, 14545-14550 (2008).
36. Horner, S.M., Park, H.S. & Gale, M. Jr. Control of innate immune signaling and membrane targeting by the hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. J. Virol. 86, 3112-3120 (2012).
37. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 (2011).
38. Leslie, A.G.W. & Powell, H.R. Processing difraction data with Mosfm. in Evolving Methods for Macromolecular Crystallography 245, 41-51 (2007).
39. Kabsch, W. Integration, scaling, spacegroup-assignment and post-refnement. Acta Crystallogr. D Biol. Crystallogr. 66, 133-144 (2010).
40. Collaborative Computational Project, Number 4. Te CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
41. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004). (Pubitemid 41742764)
42. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refnement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997). (Pubitemid 27235885)
43. Bricogne, G. et al. BUSTER version 1.11.2. (Global Phasing Ltd., 2011).
44. Mooij, W.T.M. et al. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem 1, 827-838 (2006). (Pubitemid 44384544)